Sentences with phrase «as nuclear factor»

Not exact matches

With massive and increasing structural deficits; exploding debt in all sectors; hostile demographics; social and political fracturing and disintegration; grotesque wealth inequality; extraordinary global trade competition; a complete collapse of respect for vital government organizations such as the Justice Department and FBI, which the people now realize have gone rogue; an extremely complex and corrosive global geopolitical environment; the real prospect of war, potentially nuclear and worldwide; not to mention numerous additional factors, we can only point to few other times in history more dangerous to the people's financial welfare, and therefore more overall bullish for gold, one of the only financial sanctuaries proven to work in times of dislocation.

@Chad: I. Mutations in DNA sequences generally occur through one of two processes: A. Environmental factors: DNA damage from environmental agents such as ultraviolet light (sunshine), nuclear radiation or certain chemicals B. Mistakes that occur when a cell copies its DNA in preparation for cell division.

The faith - group programs, representing Protestant, Catholics, and Jews, have consistently provided documentaries, dramas, and discussions which dealt with issues almost never touched by commercial broadcasting: the economic factors behind nuclear armaments; the issues behind draft evasion (during the Vietnam War); the real causes of worldwide starvation; and the problems of people who are ignored almost completely by the media, such as the aging who can not live on their pensions, unwed mothers, farm workers who have no homes, undocumented aliens whom we wish to employ but not pay, and refugees we are sending back to certain death in their own countries.

Other factors that played into the decision included the growing interest in nuclear power from countries such as Turkey, Indonesia and the United Arab Emirates, Benedict said.

By building a physical framework for this motion, we can identify key factors in the nuclear structure and function as well as expand the field of stochastic polymer dynamics.

In collaboration with the University of Texas Southwestern Medical Center (UTSW) in Dallas, the researchers found that the tumor - suppressive activity of geranylgeraniol was accompanied by down - regulation of HMG CoA reductase, a key enzyme in the mevalonate pathway that provides essential intermediates for the posttranslational modification of growth - related proteins such as Ras, nuclear lamins and insulin - like growth factor receptors.

For example, nuclear factor - kappa B (NF - kB) is a complex of proteins that acts as a master switch for turning inflammation genes on and for controlling cell death.

Working with cultures of respiratory tract cells, Elias's team found that the gene that codes for il - 6 is inactive unless a protein known as nf - kb (nuclear factor - kappa beta) attaches to the gene.

They later showed that RORA, a nuclear hormone receptor that functions as a transcription factor, can potentially regulate the transcription of more than 2,500 genes, including over 400 genes already associated with autism.

As a monomer, GR represses the activities of pro-inflammatory transcription factors, such as activator protein 1 or nuclear factor kappa B (NF - kB) by a tethering mechanism called transrepressioAs a monomer, GR represses the activities of pro-inflammatory transcription factors, such as activator protein 1 or nuclear factor kappa B (NF - kB) by a tethering mechanism called transrepressioas activator protein 1 or nuclear factor kappa B (NF - kB) by a tethering mechanism called transrepression.

The branch uniting the fungi and animals is well - supported based on a number of molecular phylogenetic datasets, including the nuclear small subunit ribosomal RNA gene (Wainwright et al., 1993; Bruns et al. 1993), unique and shared sequence insertions in proteins such as elongation factor 1α (Baldauf and Palmer, 1993), entire mitochondrial genomes (Lang et al., 2002), and concatenated protein - coding genes (Steenkamp et al., 2006).

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transnuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transNuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

Receptor - interacting protein kinase 2 (RIP2 or RICK, herein referred to as RIPK2) is linked to the pathogen pathway that activates nuclear factor κ - light - chain - enhancer of activated B cells (NFκB) and autophagic activation.

These markers include nuclear foci of phosphorylated histone H2AX and their co-localization with DNA repair and DNA damage checkpoint factors such as 53BP1, MDC1 and NBS1.

Another terpene, α - pinene is released by plants as a volatile defense mechanism, yet seems to decrease inflammation by inhibiting NF - κB (Nuclear Factor Kappa B).11 NF - κB regulates our immune response and is turned on in response to harmful states like infection.

Another more common example is cigarette smoke, which causes chronic inflammation in the lungs, producing oxidation (and free - radicals) and leads to DNA damage and chronic obstructive pulmonary disease as well as lung cancer.6 A hallmark of both of these processes in the activation of nuclear factor - Kappa B (NF - KB), which is a protein complex that the body produces in response to inflammation, free radicals, cytokines, all hallmarks of stress.

In addition, LA promoted inflammatory processes activating the nuclear factor - κB transcription factor as well as stimulating the expression of cyclooxygenase - 2 and pro-inflammatory cytokines.

The vitamin A — RXR - alpha complex «dimerizes» with these other nuclear receptors, forming a new complex that acts as a transcription factor to turn on gene expression.

Zinc assists in regulating an immune system protein called NF - kB (Nuclear FActor - kappa Beta) by reducing inflammation and serving as an antioxidant to prevent oxidative stress.

Several astronomical factors affect the climate of the earth; the Sun gets brighter over time as it moves along the main sequence, and the Earth gradually drifts further away from the sun as the mass of the sun drops (Solar wind, nuclear conversion).

Rough calculations show if you drill about a dozen mine shafts as deep as possible into the thing, and plunk megaton nuclear bombs down there, and then fire them off simultaneously, you'll get a repeat of the Long Valley Caldera explosion of about 800,000 years ago — which coated everything east of it with miles of ash and injected a giant aerosol cloud into the stratosphere — the ash layer alone formed a triangle stretching from the caldera to Louisiana to North Dakota, including all of Arizona and most of Idaho and everything in between — I bet that would have a cooling factor of at least -30 W / m ^ 2 — and you could go and do the Yellowstone Plateau at the same time — geoengineering at its finest.

They agree with me in such statements as «'' A critical factor for the future of an expanded nuclear power industry is the choice of the fuel cycle — what type of fuel is used, what types of reactors «burn» the fuel, and the method of disposal of the spent fuel.

He pointed to the NRC as a factor in the closing of the Vermont Yankee nuclear power plant, but failed to mention the plant had been plagued by problems in recent years, including

He pointed to the NRC as a factor in the closing of the Vermont Yankee nuclear power plant, but failed to mention the plant had been plagued by problems in recent years, including a cooling tower collapse and radioactive tritium leak.

With wind forecasting, changes in wind energy output are factored into grid operations much like variations in demand — both change over a matter of 30 minutes or even hours (not a matter of seconds, such as when fossil - fuelled or nuclear plants experience an unexpected outage, or a tree falls on a transmission line).

Nuclear power would provide many other benefits as well: energy security, reliable energy supply, reduce shipping costs and energy used in shipping coal by a factor of 20,000 to 2 million, provide fresh water, no need for carbon pricing, avoid 1 million fatalities per year by 2050,... https://judithcurry.com/2012/08/17/learning-from-the-octopus/#comment-231867.

Add to this the fact that an increase in nuclear reactors will lead to a depletion of uranium stocks within a century - unless you factor in «breeder reactors» that have so far been shunned as they can produce weapons - grade nuclear materials - and nuclear ambitions start to look decidedly shaky.

http://www.brookings.edu/~/media/research/files/papers/2014/05/19%20low%20carbon%20future%20wind%20solar%20power%20frank/net%20benefits%20final.pdf «As shown in Tables 2A and 2B, among the no - carbon energy alternatives, nuclear plants avoid the most emissions per MW of new capacity, simply because nuclear plants have far and away the highest capacity factor.

-- Muller believes humans are changing climate with CO2 emissions — humans have been responsible for «most» of a 0.4 C warming since 1957, almost none of the warming before then — IPCC is in trouble due to sloppy science, exaggerated predictions; chairman will have to resign — the «Climategate» mails were not «hacked» — they were «leaked» by an insider — due to «hide the decline» deception, Muller will not read any future papers by Michael Mann — there has been no increase in hurricanes or tornadoes due to global warming — automobiles are insignificant in overall picture — China is the major CO2 producer, considerably more than USA today — # 1 priority for China is growth of economy — global warming is not considered important — China CO2 efficiency (GDP per ton CO2) is around one - fourth of USA today, has much room for improvement — China growth will make per capita CO2 emissions at same level as USA today by year 2040 — if it is «not profitable» it is «not sustainable» — US energy future depends on shale gas for automobiles; hydrogen will not be a factor — nor will electric cars, due to high cost — Muller is upbeat on nuclear (this was recorded pre-Fukushima)-- there has been no warming in the USA — Muller was not convinced of Hansen's GISS temperature record; hopes BEST will provide a better record.

Other alternatives such as fuel from foodstocks, liquifaction of coal, nuclear, solar thermal, windmills, etc. are pretty far removed from the Moore's Law enabling factors so you're on target there but you didn't need to spray the guy with a mini-gun when far less would suffice to make your point.

Nevertheless, as shown in the figure, these combined capacity factors for wind and solar are far less than those for the dispatchable technologies — natural gas, coal, and nuclear.

As an example, the 1,532 MW of emissions - free Bruce Nuclear refurbished generation, at a capacity factor of 90 % supplying 12.08 TWh, easily covered the loss of 4.1 TWh of coal - fired generation and left 8.7 TWh for added demand due to its flexibility to steam off or bypass the turbines.

The indicators emissions per capita, emissions per GDP and CO2 / kWh are adjusted as if the generation of electricity from nuclear power had produced 350 gCO2 / kWh (emission factor for natural gas).

The main reason was that growth in renewables and nuclear power could not keep up with increased electricity demand, even though some sources have cited a drought - induced drop in hydropower output as a factor in the rebounding coal consumption.

On the other hand, it is reasonable to assume that natural market factors will gradually result in a reduction of ever more expensive fossil fuel combustion as older coal - fired power plants are shut down and replaced by nuclear plants, as hybrid and electrical cars gradually replace gasoline and diesel driven ones, and as energy efficiency is improved and waste reduced.

[3] Each state has interim targets it must meet beginning in 2020, and the EPA proposed that states use a combination of four «building blocks» to achieve the emissions reductions: (1) improving the efficiency (heat rate) of existing coal - fired power plants; (2) switching from coal - fired power by increasing the use and capacity factor, or efficiency, of natural - gas combined - cycle power plants; (3) using less carbon - intensive generating power, such as renewable energy or nuclear power; and (4) increasing demand - side energy - efficiency measures.

Owing to their high capital cost, low fuel cost, and high capacity factors, technologies such as coal and nuclear were designed to operate continuously to meet the base - load demand component.

The indicators «emissions per capita», «emissions per GDP» and «CO2 per kWh electricity» for all countries have therefore been adjusted as if the generation of electricity from nuclear power had produced 350 gCO2 / kWh (emission factor for natural gas).

The so called Renewable Energy technologies such as Wind and Solar even if further refined and made more efficient, sought after efficiency increases that are now running into the problems of ever diminishing returns for the investments needed to raise those levels of efficiency, are now just one of the limiting factors in the hope of the so called Renewable Energy systems ever replacing today's base load coal, gas, oil, nuclear powered generators.

«Wind and solar's «capacity factor» or availability to supply power is around 33 %, which means 67 % of the time wind and solar can not supply power and must be supplemented by a traditional energy source such as nuclear, natural gas or coal.

Wind power is 42 % more expensive than nuclear and natural gas power... Wind and solar's» «capacity factor» or availability to supply power is around 33 %, which means 67 % of the time wind and solar can not supply power and must be supplemented by a traditional energy source such as nuclear, natural gas or coal.»

Nuclear in France, US and China all use hydro to enable nuclear to operate at a high capacity factor, as does wind in DNuclear in France, US and China all use hydro to enable nuclear to operate at a high capacity factor, as does wind in Dnuclear to operate at a high capacity factor, as does wind in Denmark.

Due to factors such as wind direction, the nuclear blast released radiation «in a very patchy manner, so while the highest areas of contamination are closest to the plant, there are also areas of higher radiation quite a ways away from the reactor,» Mousseau said.

Occurrence of depressive tendency and associated social factors among elderly persons forced by the Great East Japan Earthquake and nuclear disaster to live as long - term evacuees: a prospective cohort study

The market for such homes has expanded in recent years as economic factors and demographic shifts have reshaped the nuclear family and altered its housing needs.